Back to News
Market Impact: 0.15
Oculis Completes Randomization in PREDICT-1 Registrational Trial of Licaminlimab for TNFR1-Mediated Dry Eye Disease
Source: globenewswire.com
Healthcare & Biotech
Two-thirds of the 176 enrolled patients carry the TNFR1 genetic variant, which was previously linked to enhanced clinical response in Phase 2 trials. The enrollment profile indicates target enrichment but does not report new clinical outcomes.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
More News
- Crushed tech stocks bounce — plus, new doctor survey keeps us positive on Lilly
- Capital One, General Motors are among the stocks reporting this week with momentum. Here are the others
- Merck KGaA to acquire Silence Therapeutics for $1.3 billion
- Disc Medicine surges 38% after bitopertin clears Phase 3 trial endpoints
- Silence Therapeutics jumps 59% on Merck takeover
- Goldman says play defense with these stocks if you're worried about the AI bull failing